

CLAIMS

1. A compound of formula (I) or (I'), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof,



(I),




(I')

wherein:

X_1 and X_2 are each independently selected from the group consisting of a bond, $-(CH_2)_n-$, $-CH(R^1)(CH_2)_n-$, -C(O)-, and $-S(O)_2-$;

Ring A is independently selected from the group consisting of C_6-C_{10} aryl, monocyclic 5- or 6-membered heteroaryl, bicyclic 9- or 10-membered heteroaryl, and tricyclic 12-, 13- or 14-membered heteroaryl, wherein the heteroaryl has 1, 2 or 3 heteroatoms as ring members which are each independently selected from the group consisting of O, S, and N, wherein the aryl, and heteroaryl are optionally substituted with 1 to 6 identical or different substituents R^2;

Ring B is independently selected from the group consisting of C_3-C_8 cycloalkyl, 4 to 10 membered monocyclic or bicyclic heterocyclyl, C_6-C_{10} aryl, 5 to 10-membered heteroaryl, wherein the heterocyclyl, and heteroaryl have 1, 2 or 3 heteroatoms as ring members which are each independently selected from the group consisting of O, S, and N; wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with 1 to 6 identical or different substituents R^3;

Ring C is independently selected from the group consisting of 

,

Ring D is independently selected from the group consisting of C_3-C_8 cycloalkyl, 3 to 8-membered heterocyclyl, C_6-C_{10} aryl, and 5 to 10-membered heteroaryl, wherein the heterocyclyl, and heteroaryl have 1, 2 or 3 heteroatoms as ring members which are each independently selected from the group consisting of O, S, and N; wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with 1 to 6 identical or different

substituents R^5;

Ring E is independently selected from the group consisting of C_3-C_8 cycloalkyl, 3 to 8-membered heterocyclyl, C_6-C_{10} aryl, and 5 to 10-membered heteroaryl, wherein the heterocyclyl, and heteroaryl have 1, 2 or 3 heteroatoms as ring members which are each independently selected from the group consisting of O, S, and N; wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with 1 to 6 identical or different substituents R^6;

wherein n is 0, 1, 2 or 3,

the H in $-(CH_2)_n-$ can be optionally substituted with deuterium, C_1-C_6 alkyl, and halogen;

each R^1 is independently selected from the group consisting of H, deuterium, C_1-C_6 alkyl, and halogen;

each R^2 is independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, cyano, C_1-C_6 alkyl, and C_1-C_6 haloalkyl;

each R^3 and R^5 is independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, cyano, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_2-C_6 alkenyloxy, C_2-C_6 alkynyloxy, C_2-C_6 alkanoyl, C_2-C_6 alkylester, C_1-C_6 thioalkyl, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, hydroxy C_1-C_6 alkyl, C_3-C_7 cycloalkyl, and 3 to 8-membered heterocyclyl, wherein the cycloalkyl, and heterocyclyl are optionally substituted with halogen, CN and -OMe;

each R^6 is independently selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, -CN, –OH, C_3-C_8 cycloalkyl, 3 to 8-membered heterocyclyl, nitro, amino, mercapto, -COOH, C_2-C_6alkenyl, C_2-C_6alkynyl, C_2-C_6alkenyloxy, C_2-C_6alkynyloxy, C_2-C_6alkanoyl, C_2-C_6alkylester, C_1-C_6thioalkyl, hydroxyC_1-C_6alkyl, aminoC_1-C_6alkyl, (mono- and di-C_1-C_6alkylamino)C_0-C_4alkyl, -C_0-C_4alkyl(C_3-C_7cycloalkyl), -O-C_0-C_4alkyl(C_3-C_7cycloalkyl), -C_0-C_4alkyl-(phenyl), -C_0-C_4alkylOC(O)OC_1-C_6alkyl, -C_0-C_4alkylOC(O)C_1-C_6alkyl, -C_0-C_4alkylC(O)OC_1-C_6alkyl, C_0-C_4alkyl-(4- to 7-membered heterocycloalkyl) having 1, 2, or 3 heteroatoms independently chosen from N, O, and S, and C_0-C_4alkyl-(5- or 6-membered unsaturated or aromatic heterocycle) having 1, 2, or 3 heteroatoms independently chosen from N, O, and S, -C(O)OR^7, -C_0-C_4alkylNR^7R^8, -C(O)NR^7R^8, -SO_2R^7, -SO_2NR^7R^8, -OC(O)R^7, and -C(NR^7)NR^7R^8, wherein R^7 and R^8 are independently chosen from hydrogen, C_1-C_6alkyl, -C_0-C_4alkyl(C_3-C_7cycloalkyl), and -O-C_0-C_4alkyl(C_3-C_7cycloalkyl);

R_m is halogen;


X'_1 is $-(CH_2)_m-$;

Ring B' is independently selected from the group consisting of C_3-C_8 cycloalkyl, 4 to 10 membered monocyclic or bicyclic heterocyclyl, wherein the heterocyclyl has 1, 2 or 3 heteroatoms as ring members which are each independently selected from the group consisting of O, S, and N;

R_{n1} and R_{n2} are each independently selected from the group consisting of halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, -CN, –OH, C_3-C_8 cycloalkyl, 4 to 10 membered monocyclic or bicyclic heterocyclyl, C_6-C_{10} aryl, and 5 to 10-membered heteroaryl; wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1 to 6 identical or different substituents selected from the group consisting of halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, -CN, –OH, C_3-C_8 cycloalkyl, 4 to 10 membered monocyclic or bicyclic heterocyclyl;

the H in $-(CH_2)_m-$ can be optionally substituted with deuterium, C_1-C_6 alkyl, and halogen;

m is 0,1, 2, or 3.

2. The compound of claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ring A is 9-membered heteroaryl, and preferably, Ring A is 


;

wherein ------ is a single bond or a double bond;

R^2 is independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, cyano, C_1-C_6 alkyl, and C_1-C_6 haloalkyl;

Y_1, Y_2, Y_3, Y_4 and Y_5 are each independently selected from the group consisting of C, CH, N, O, S and CO;

W_1, W_2, W_3 and W_4 are each independently selected from the group consisting of C, and N.

3. The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ring B is 

;


Y_6 is independently selected from the group consisting of CH and N;

Z_1 and Z_2 are each independently selected from the group consisting of CH and N;


each R^3 is independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, cyano, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_2-C_6 alkenyloxy, C_2-C_6 alkynyloxy, C_2-C_6 alkanoyl, C_2-C_6 alkylester, C_1-C_6 thioalkyl, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, hydroxy C_1-C_6 alkyl, C_3-C_7 cycloalkyl, and 3 to 8-membered heterocyclyl, wherein the cycloalkyl, and heterocyclyl are optionally substituted with halogen, CN and –OMe;

p is 0, 1, 2, 3 or 4.


4. The compound of claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, having a Formula (II-1)-(II-3),



(II-1)



(II-2)



(II-3)

wherein, each X_2 is independently selected from the group consisting of a bond, $-(CH_2)_n-$, $-CH(R^1)(CH_2)_n-$, -C(O)-, and $-S(O)_2-$;

Y_6 is independently selected from the group consisting of CH and N;


p is 0, 1, 2, 3 or 4;

n is 0, 1, 2 or 3;

R^1, R^2, R^3, Ring D and Ring E are defined as claim 1.

5. The compound of claim 4, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound has a structure of


formula (III)



(III)

R^2, R^3, X_2, p, Y_6, Ring D and Ring E are as defined in claim 4.


6. The compound of claim 4, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound has a structure of formula (IV)




(IV)

R^2, R^3, X_2, Y_6, Ring D and Ring E are as defined in claim 4.

7. The compound of claim 4, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound has a structure represented by a formula selected from the following formulas:




(IV-1)




(IV-2)

wherein R^2, R^3, X_2, Y_6, Ring D and Ring E are as defined in claim 4.


8. The compound of claim 4, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound has a structure represented by a formula selected from the following formulas:




(V-1)



(V-2)







(V-3)



(V-4)








R^2, R^3, X_2, Y_6, Ring D and Ring E are as defined in claim 4.

9. The compound of claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ring D is selected from the group consisting of C_3-C_7 cycloalkyl (preferably, C_3-C_6 cycloalkyl), 4-8-membered heterocyclyl (preferably, 4-7-membered heterocyclyl), wherein the cycloalkyl and heterocyclyl are optionally substituted with 1 to 6 identical or different substituents R^5;

preferably, Ring D is selected from the group consisting of , ,  and ;

wherein, each R^5 is independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, cyano, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_2-C_6 alkenyloxy, C_2-C_6 alkynyloxy, C_2-C_6 alkanoyl, C_2-C_6 alkylester, C_1-C_6 thioalkyl, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, hydroxy C_1-C_6 alkyl, C_3-C_7 cycloalkyl, and 3 to 8-membered heterocyclyl, wherein the cycloalkyl, and heterocyclyl are optionally substituted with halogen, CN and -OMe; or two R^5 on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring;


Y_7 is independently selected from the group consisting of CH and N;

q is 0, 1, 2 or 3;more preferably, Ring D is selected from the group consisting of , , , , ,  and ;


more preferably, each R^5 is independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, cyano, C_1-C_3 alkyl, C_3-C_7 cycloalkyl, C_1-C_3 haloalkyl;

wherein when q is greater than or equal to 2, two R^5 are optionally taken together with atoms to which they are bound to form a carbocyclyl or heterocyclyl ring.


10. The compound of claim 2, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound has a structure represented by a formula selected from the following formulas:




(VI-1)



(VI-2)



(VI-3)



(VI-4)

wherein Y_6 is independently selected from the group consisting of CH and N;


Y_7 is independently selected from the group consisting of CH and N;

each R^5 is independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, cyano, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_2-C_6 alkenyloxy, C_2-C_6 alkynyloxy, C_2-C_6 alkanoyl, C_2-C_6 alkylester, C_1-C_6 thioalkyl, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, hydroxy C_1-C_6 alkyl, C_3-C_7 cycloalkyl, and 3 to 8-membered heterocyclyl, wherein the cycloalkyl, and heterocyclyl are optionally substituted with halogen, CN and -OMe; or two R^5 on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring;


q is 0, 1, 2 or 3

R^2, R^3, X_2, and Ring E are as defined in claim 1.

11. The compound of claim 10, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound has a structure represented by a formula selected from the following formulas:




(VII-1)




(VII-2)

wherein R^2, R^3, R^5, X_2, q, Y_6, and Ring E are as defined in claim 10.

12. The compound of claim 11, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound has a structure represented by a formula selected from the following formulas:



(VIII-1)



(VIII-2)

wherein R^2, R^3, R^5, X_2, q, Y_6, and Ring E are as defined in claim 11.





13. The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ring E is a 5- to 9- membered heteroaryl, wherein the heteroaryl have 1, 2 or 3 heteroatoms as ring members which are each independently selected from the group consisting of O, S, and N; wherein the heteroaryl are optionally substituted with 1 to 3 identical or different substituents R^6;


wherein each R^6 is independently selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, -CN, –OH, C_3-C_8 cycloalkyl, 3 to 8-membered heterocyclyl.

14. The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ring E is selected from the group consisting of C_3-C_6 cycloalkyl, 4-6 membered heterocyclyl, thiazolyl, imidazolyl, oxazolyl, isoxazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, and pyrazinyl, pyrazolyl, indazolyl; wherein the cycloalkyl, heterocyclyl, thiazolyl, imidazolyl, oxazolyl, isoxazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrazolyl, indazolyl are optionally substituted with 1 to 6 identical or different substituents R^6;

wherein, each R^6 is independently selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_2-C_6 alkynyl, C_2-C_6 alkynyloxy, -CN, –OH, C_3-C_8 cycloalkyl, 3 to 8-membered heterocyclyl, C_5-C_{10} heteroaryl;

e is 0, 1, 2, 3, 4, or 5;


more preferably, Ring E is selected from the group consisting of Ring E is selected from the group consisting of , , , ,



wherein, each R^6 is independently selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, -CN, –OH, C_3-C_8 cycloalkyl, 3 to 8-membered heterocyclyl;















e is 0, 1, 2, 3, 4, or 5;





more preferably, Ring E is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,



























.



15. The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which is selected from the group consisting of:































































5

































































































































































































































16. The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which is selected from the group consisting of:





17. A pharmaceutical composition comprising a compound of any one of claims 1-16, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.

18. Use of a compound of any one of claims 1-16 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof in the manufacture of a medicament for the treatment of a disease or disorder that is affected by the degradation of WIZ protein.